secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001104659-24-026303
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls
------------------------------------------------------------------------------

- Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).
- Cash $275.8M at Dec 31, 2023; 2024 non-GAAP op expense guidance $250-270M.
- Material weakness in IT general controls over user access and program change management expected in 10-K.
- Completed enrollment in Phase 3 hypothalamic obesity trial (N=120); top-line data 1H2025.
- Entered global licensing deal for oral MC4R agonist LB54640; IND accepted for RM-718.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/0001104659-24-026303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/tm246832d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-026303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer